Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0E0TD
|
||||
| Former ID |
DNC007804
|
||||
| Drug Name |
4-(4-((phenethylamino)methyl)phenoxy)benzamide
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [528996] | ||
| Formula |
C22H22N2O2
|
||||
| Canonical SMILES |
C1=CC=C(C=C1)CCNCC2=CC=C(C=C2)OC3=CC=C(C=C3)C(=O)N
|
||||
| InChI |
1S/C22H22N2O2/c23-22(25)19-8-12-21(13-9-19)26-20-10-6-18(7-11-20)16-24-15-14-17-4-2-1-3-5-17/h1-13,24H,14-16H2,(H2,23,25)
|
||||
| InChIKey |
FARQYUHOSNLRKV-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Kappa-type opioid receptor | Target Info | Inhibitor | [528996] | |
| Delta-type opioid receptor | Target Info | Inhibitor | [528996] | ||
| Mu-type opioid receptor | Target Info | Inhibitor | [528996] | ||
| NetPath Pathway | TCR Signaling Pathway | ||||
| PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||||
| Opioid prodynorphin pathwayP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||||
| Enkephalin release | |||||
| Opioid proenkephalin pathway | |||||
| Opioid proopiomelanocortin pathwayP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||||
| Pathway Interaction Database | IL4-mediated signaling events | ||||
| References | |||||